Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01570036
Recruitment Status : Active, not recruiting
First Posted : April 4, 2012
Last Update Posted : April 6, 2018
Genentech, Inc.
Sellas Life Sciences Group
Information provided by (Responsible Party):
George E. Peoples, Cancer Insight, LLC

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : June 2019
  Estimated Study Completion Date : June 2020